Lenalidomide Stada Arzneimittel Ag

Lenalidomide, the active ingredient in Lenalidomide Stada Arzneimittel Ag, is a immunomodulatory drug presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), mantle cell lymphoma and follicular lymphoma in adult patients.

GNH USA supplies Lenalidomide Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in the treatment of hematologic malignancies and related disorders. - Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: contributes to disease control in patients who have received prior therapies. - Follicular Lymphoma: used in combination regimens to achieve higher response rates.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: mild skin eruptions or itching. - Nausea: feeling of sickness that may be transient.

Serious or Rare Side Effects: - Thromboembolic events: blood clots such as deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating Lenalidomide therapy, several precautions should be considered to ensure safe use. - Pregnancy risk: contraindicated in pregnancy due to teratogenicity; effective contraception required. - Thrombosis prophylaxis: assess need for anticoagulation in patients with high clot risk. - Renal function: dose adjustment may be needed in impaired kidney function. - Hematologic monitoring: regular blood counts required to detect cytopenias. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with Lenalidomide. - Immunosuppressants (e.g., cyclosporine): may enhance immunosuppressive effects.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase Lenalidomide exposure. - Hormonal contraceptives: reduced effectiveness, additional contraceptive methods advised. - Vaccines: live vaccines should be avoided due to immunomodulatory effects.